Saikosaponin A

Name: Saikosaponin A
Brand: MedChemExpress
SKU: HY-N0246
Rating: 5.0 (5 reviews)

Cat. No.: HY-N0246 Purity: 99.31%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis.

For research use only. We do not sell to patients.

CAS No. : 20736-09-8

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Saikosaponin A:

Saikosaponin A (Standard) Get quote

5 Publications Citing Use of MCE Saikosaponin A

RT-PCR

Histological Imaging/Staining

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Cardiomyocytes were pretreated with Saikosaponin A (SSA) (1, 10 and 30 µmol/L) for 1 h then exposed to IAA (50 µmol/L) for 48 h and mRNA expression levels of ANP, BNP and β-MHC were analyzed by qPCR.

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Cardiomyocytes were pretreated with Saikosaponin A (SSA) (30 µmol/L) for 1 h and then exposed to IAA (50 µmol/L) for 48 h and Trim16 protein expression measured by Western blotting.

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Representative micrographs (magnification, 10×) of hematoxylin and eosin-stained transverse sections from hearts of control, IAA- and IAA + Saikosaponin A (SSA) (40 mg/kg, i.g.)-treated mice.

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Cardiomyocytes were transfected with siTrim16 or scrambled siRNA (siCntl), treated with Saikosaponin A (SSA) (30 µmol/L) for 1 h, then incubated with IAA (50 µmol/L) for 48 h. K48 ubiquitination of RIP2 was measured by immunoprecipitation.

: Saikosaponin A purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2023 Sep;28(3):159. [Abstract]; Cell size was observed by immunofluorescence using a troponin antibody treated with Saikosaponin A (SSA) (30 µmol/L).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	23.9 μM Compound: 1	Cytotoxicity against human A375 cells after 48 hrs by SRB assay Cytotoxicity against human A375 cells after 48 hrs by SRB assay	[PMID: 19467877]
A549	IC₅₀	14.54 μM Compound: 8	Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human A549 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
A549	IC₅₀	17.7 μM Compound: 1	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 19467877]
ACHN	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay Cytotoxicity against human ACHN cells after 48 hrs by SRB assay	[PMID: 19467877]
Bcap37	IC₅₀	13.96 μM Compound: 8	Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Bcap37 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
C32	IC₅₀	43.5 μM Compound: 1	Cytotoxicity against human C32 cells after 48 hrs by SRB assay Cytotoxicity against human C32 cells after 48 hrs by SRB assay	[PMID: 19467877]
COR-L23	IC₅₀	0.6 μM Compound: 1	Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay Cytotoxicity against human COR-L23 cells after 48 hrs by SRB assay	[PMID: 19467877]
Caco-2	IC₅₀	17.9 μM Compound: 1	Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay Cytotoxicity against human Caco-2 cells after 48 hrs by SRB assay	[PMID: 19467877]
Hep 3B2	IC₅₀	13.01 μM Compound: 8	Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human Hep3B cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
HepG2	IC₅₀	8.34 μM Compound: 8	Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human HepG2 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
LNCaP	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay	[PMID: 19467877]
MCF7	IC₅₀	18.99 μM Compound: 8	Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay Cytotoxicity against human MCF7 cells assessed as induction of cell death incubated for 2 days by MTT assay	[PMID: 26259802]
MCF7	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 19467877]
RAW264.7	IC₅₀	101.8 μM Compound: 1	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method	[PMID: 19467877]
RAW264.7	IC₅₀	> 200 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 19467877]

In Vitro

Saikosaponin A (5-15 μM, 24 h) did not affect the viability of human osteoarthritis chondrocytes^[1].
Saikosaponin A (5-15 μM, 24 h) inhibits IL-1β (HY-P73149)-induced NO and PGE2 production and NF-κB activation^[1].
Saikosaponin A (5-15 μM, 24 h) up-regulates the expression of LXRα in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Human osteoarthritis chondrocytes
Concentration:	5, 10, 15 μM
Incubation Time:	24 h
Result:	Inhibited the levels of phosphorylation of NF-κB p65 and IκBα induced by IL-1β. Up-regulated the expression of LXRα in a dose-dependent manner.

In Vivo

Saikosaponin A (1-10 mg/kg, i.p, 7 d) attenuates the morphological changes in the small intestine induced by 5-FU^[2].
Saikosaponin-A (1-10 mg/kg, i.p, 7 d) enhances the decrease of antioxidant enzymes in intestinal tissue caused by 5-FU^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	5-FU (HY-90006)-induced mucositis in BALB/c mice modle^[2]
Dosage:	1, 5, 10 mg/kg/day, 7 d
Administration:	injected intraperitoneally (i.p)
Result:	Reduced villus blunting, crypt cells apoptosis, and inflammatory cell infiltration. Decreased concentration of GSH, GST, Catalase, and SOD in intestinal tissue.

Molecular Weight

780.98

Formula

C₄₂H₆₈O₁₃

CAS No.

20736-09-8

Appearance

Solid

Color

White to off-white

SMILES

OC[C@H]1O[C@](O[C@@H]2[C@@H](O)[C@@](O[C@@H]3[C@@](C)(CO)[C@@](CC[C@]4(C)[C@]5([H])C=C[C@@]6(OC7)[C@@]4(C)C[C@H](O)[C@]87[C@@]6([H])CC(C)(C)CC8)([H])[C@]5(C)CC3)([H])O[C@H](C)[C@@H]2O)([H])[C@H](O)[C@@H](O)[C@@H]1O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (128.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2804 mL	6.4022 mL	12.8044 mL
5 mM	0.2561 mL	1.2804 mL	2.5609 mL
10 mM	0.1280 mL	0.6402 mL	1.2804 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (12.80 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.31%

Select Batch:

Data Sheet (282 KB) SDS (394 KB)

COA (253 KB) LCMS (100 KB)

Handling Instructions (2659 KB)

References

[1]. Gao H, et al. Saikosaponin A inhibits IL-1β-induced inflammatory mediators in human osteoarthritis chondrocytes by activating LXRα. Oncotarget. 2017 Sep 30;8(51):88941-88950. [Content Brief]

[2]. Jawad Ali, et al. Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Life Sci. 2019. [Content Brief]

[3]. Feng P, et al. Saikosaponin a attenuates hyperlipidemic pancreatitis in rats via the PPAR‑γ/NF‑κB signaling pathway[J]. Experimental and therapeutic medicine, 2020, 19(2): 1203-1212. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.2804 mL	6.4022 mL	12.8044 mL	32.0111 mL
	5 mM	0.2561 mL	1.2804 mL	2.5609 mL	6.4022 mL
	10 mM	0.1280 mL	0.6402 mL	1.2804 mL	3.2011 mL
	15 mM	0.0854 mL	0.4268 mL	0.8536 mL	2.1341 mL
	20 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6006 mL
	25 mM	0.0512 mL	0.2561 mL	0.5122 mL	1.2804 mL
	30 mM	0.0427 mL	0.2134 mL	0.4268 mL	1.0670 mL
	40 mM	0.0320 mL	0.1601 mL	0.3201 mL	0.8003 mL
	50 mM	0.0256 mL	0.1280 mL	0.2561 mL	0.6402 mL
	60 mM	0.0213 mL	0.1067 mL	0.2134 mL	0.5335 mL
	80 mM	0.0160 mL	0.0800 mL	0.1601 mL	0.4001 mL
	100 mM	0.0128 mL	0.0640 mL	0.1280 mL	0.3201 mL

Saikosaponin A Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Saikosaponin A20736-09-8LXRBacterialLiver X receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Saikosaponin A

Customer Review

Other Forms of Saikosaponin A:

Saikosaponin A Related Antibodies

5 Publications Citing Use of MCE Saikosaponin A

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Saikosaponin A Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Saikosaponin A Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report